Q Fever Market Research Report - Global Forecast till 2027

Global Q fever market information: by Type (Acute & Chronic), by Diagnosis (Serology Tests, & Others), and by Treatment (Antibiotics & Surgery) by Region (Asia Pacific, Europe, North America, Latin America, and Middle East &Africa)—Forecast till 2027

ID: MRFR/Pharma/4044-CR | April 2019 | Region: Global | 123 pages

Please note that the assessment period of report has been updated from 2019-2023 to 2020-2027. Cordially fill the sample form for updated data.

The Global Q fever market is expected to grow at CAGR of 7.83% to reach USD 6,249.68 thousand till 2023. Some of the protuberant drivers supporting the growth of the global Q fever market are identified as growth in the prevalence of chronic diseases and the increasing number of patients suffering from various bacterial infections.


The rising prevalence of Q fever coupled with increasing Q fever hospitalization rates, rising worldwide cattle, sheep, and goat population, growth in the risk factors of Q fever, and globally growing geriatric population are expected to drive the global Q fever market in coming years.


Synopsis/Market Dynamics


Q fever is a bacterial infection caused by the bacteria Coxiella (C.) burnetii. C. burnetii has a reservoir in birds and mammals, especially cattle, sheep, and goats, and is most often an occupational disease affecting farmers, veterinarians, and slaughterhouse workers. The Q fever infection, mostly chronic Q fever is severe with complications including endocarditis, encephalitis, pneumonia, hepatitis, and splenomegaly requiring hospitalization. As per the data provided by the Centers for Disease Control and Prevention (CDC), between 2002 and 2014, the Q fever hospitalization rates were increased from 25.0% to 68.0%. In the US, the prevalence of Q fever was high in four states, namely, California, Texas, Colorado, and Illinois. Additionally, in 2014, the highest incidence rate of Q fever which was at least 1.0 case per million persons was found in Arizona, Arkansas, Colorado, Idaho, Montana, Nebraska, North Dakota, Oregon, South Dakota, Utah, and West Virginia. Moreover, according to the European Centre for Disease Prevention and Control (ECDC), in 2016, 1,102 cases of Q fever were reported in the European Union (EU)/European Economic Area (EEA), out of which 1,058 (96%) were confirmed.


Global Q fever Market Revenue, by Type, 2017 & 2023 (USD Mn)


Global Q fever Market Revenue, by Type, 2017 & 2023


Segmentation


Global Q fever, by type, segmented into acute and chronic. Chronic is the leading segment, which is growing at the highest CAGR to reach USD 706.20 thousand by the end of 2023. Chronic Q fever is a life threating problem and causes damage to the heart, lungs, liver, brain, and could cause diabetes as well. The major share of the chronic segment is attributed to its high prevalence.


Based on diagnosis, Q fever market is segmented into serology tests and others. The serology tests account for major share with 8.32% CAGR during the forecast period. Under the serology test, Q fever is diagnosed through antibody blood tests, polymerase chain reaction (PCR) tests, immunoperoxidase staining, complement fixation, enzyme-linked immunosorbent assay (ELISA) tests, and other molecular tests.


The Q fever market, by treatment, is segmented into antibiotic and surgery. The antibiotics segment accounts for the second largest share in the market with 7.32% CAGR during the forecast period. Surgery is an important component of treatment if patients have extensive valvular damage or indications of heart failure.


On the basis of end user, the market is segmented into patients, hospitals and clinics, and others. The patient segment accounted for a considerable market share of 72.1% as of 2017.


Global Q fever Market Share, by Region, 2017 (%)


  Global Q fever Market Share, by Region, 2017


Regional Analysis


The Asia-Pacific accounted for the largest market share of 44.5% as of 2017 and is projected to grow at the highest CAGR of 8.57% during the forecast period. The increasing prevalence of chronic diseases such as diabetes, cancer, and bacterial infection in developing countries is the major driver for market growth. According to the International Diabetic Federation, about 415 million people had diabetes across the globe in 2015, which is expected to reach 642 million by 2040. It also stated that 98.4 million and 65.1 million diabetic population lived in China and India, respectively.  


The Asia-Pacific is followed by Europe, which accounted for a major market share. The European market is expected to grow at a strong growth rate during the forecast period owing to the availability of advanced treatment facilities and healthcare expenditure along with growing pet adoption.


The Americas accounted for a significant share in the global Q fever market. It is attributed to the increasing adoption of pets, increasing preventive treatments, and care facilities for companion animals, rising technically advanced devices, and growing awareness regarding animal-transmitted diseases.


Key Players


The prominent players in the global Q fever market are Merck KGaA (Germany), Teva Pharmaceutical (Israel), Pfizer Inc. (US), Basilea Pharmaceutica Ltd (Switzerland), Sanofi S.A.(France), Melinta Therapeutics, Inc. (US), Bayer AG (Germany), Johnson & Johnson Services, Inc. (US), Yashica Pharmaceuticals (India), AtoxBio (US), and others. Some of the key strategies followed by the players operating in the global Q fever market were innovation, product development, acquisition, and expansion.


  • In September 2017, Basilea Pharmaceutica Ltd entered into a development, manufacturing, and commercialization agreement with Gosun Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Basilea's antibiotic ceftobiprole in China, Hong Kong, and Macao.

  • In June 2017, Sanofi signed a strategic partnership with Eurapharma in Morocco. With this, Sanofi aims to strengthen its pharmaceutical business in Morocco and another African market.

  • In June 2017, Melinta Therapeutics, Inc. got FDA approval for its antibiotic drug Baxdela (delafloxacin) for clinical indications such as infections.


Market Segmentation


Global Q fever Market, By Type



  • Acute

  • Chronic


Global Q fever Market, By Diagnosis



  • Serology Tests

  • Others


Global Q fever Market, By Treatment



  • Antibiotics

  • Surgery


Global Q fever Market, By End User



  • Patients

  • Hospitals

  • Others


Global Q fever Market, By Region



  • North America

    • US

    • Canada



  • Europe

    • Germany

    • Russia

    • France

    • Italy

    • UK

    • Rest of Europe



  • Asia Pacific

    • China

    • India

    • Japan

    • Rest of Asia Pacific



  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Rest of Latin America



  • Middle East & Africa


Available Additional Customizations



  • Company Profiles of Other Key Players

    1. Cipla Inc. (India)

    2. CSL Limited (Australia)




Intended Audience



  • Pharmaceutical Manufacturers and Suppliers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors



Frequently Asked Questions (FAQ) :


Q fever market is projected to grow at a 7.83% CAGR between 2020-2027.

The Americas is expected to lead Q fever market.

Q fever market is predicted to touch USD 6,249.68 thousand by 2023.

Increasing hospitalization rates and rising prevalence of various bacterial infections are the key factors driving the Q fever market.

Chronic and acute are the different types of acute fever.

1 Report prologue

2 Market Introduction

2.1 Definition 15

2.2 Scope of the Study 15

2.3 Assumptions & Limitations 16

2.3.1 Assumptions 16

2.3.2 Limitations 16

2.4 Market Structure 17

3 Research Methodology

3.1 Research Process 19

3.2 Primary Research 20

3.3 Secondary Research 21

3.4 Market Size Estimation 22

3.5 Forecast Model 22

4 Market Dynamics

4.1 Introduction 24

4.2 Drivers 26

4.2.1 Worldwide Rising Prevalence of Q fever Coupled with Increasing Q Fever Hospitalization Rates 26

4.2.2 Rising Worldwide Cattle, Sheep, and Goat Population 26

4.2.3 Growth in the Risk Factors of Q Fever 26

4.2.4 Globally Growing Geriatric Population 26

4.3 Restraints 27

4.3.1 High Cost of Diagnostic Tests 27

4.3.2 Lack of Awareness About Q Fever 27

4.4 Opportunity 27

4.4.1 Presence of Untapped Opportunities in the Asia-Pacific and African Regions 27

4.5 Market Trends 27

4.6 Macroeconomic Indicators 28

5 Market Factor Analysis

5.1 Porter’s Five Forces Model 30

5.1.1 Bargaining Power of Suppliers 30

5.1.2 Bargaining Power of Buyers 31

5.1.3 Threat of New Entrants 31

5.1.4 Threat of Substitutes 31

5.1.5 Rivalry 31

5.2 Supply Chain Analysis 32

5.2.1 R&D and Development 32

5.2.2 Manufacturing 32

5.2.3 Distribution & Sales 32

5.2.4 Post-Sales Monitoring 33

5.3 Investment Feasibility Analysis 33

5.4 Pricing Analysis 34

6 Global Q Fever Market, By Type

6.1 Overview 36

6.2 Acute 37

6.3 Chronic 37

7 Global Q Fever Market, By Diagnosis

7.1 Overview 39

7.2 Serology Tests 40

7.3 Others 40

8 Global Q Fever Market, By Treatment

8.1 Overview 42

8.2 Antibiotics 43

8.3 Surgery 43

9 Global Q Fever Market, By End-User

9.1 Overview 45

9.2 Patients 46

9.3 Hospitals 46

9.4 Others 47

10 Global Q Fever Market, By Region

10.1 Overview 49

10.2 Americas 51

10.2.1 North America 52

10.2.1.1 US 54

10.2.1.2 Canada 55

10.2.2 Latin America 56

10.3 Europe 57

10.3.1 Germany 59

10.3.2 France 60

10.3.3 UK 61

10.3.4 Italy 62

10.3.5 Spain 63

10.3.6 Rest of Europe 64

10.4 Asia-Pacific 65

10.4.1 Japan 67

10.4.2 China 68

10.4.3 India 69

10.4.4 Australia 70

10.4.5 South Korea 71

10.4.6 Rest of Asia-Pacific 72

10.5 Middle East & Africa 73

10.5.1 UAE 75

10.5.2 Saudi Arabia 76

10.5.3 Oman 77

10.5.4 Kuwait 78

10.5.5 Qatar 79

10.5.6 Africa 80

10.5.7 Rest of Middle East & Africa 81

11 Company Profile

11.1 Merck KGaA 83

11.1.1 Company Overview 83

11.1.2 Financial Overview 83

11.1.3 Products/Services Offered 83

11.1.4 SWOT Analysis 84

11.1.5 Key Developments 84

11.1.6 Key Strategies 84

11.2 Teva Pharmaceutical Industries Ltd 85

11.2.1 Company Overview 85

11.2.2 Financial Overview 85

11.2.3 Products/Services Offered 86

11.2.4 Key Developments 86

11.2.5 SWOT Analysis 86

11.2.6 Key Strategies 86

11.3 Pfizer Inc. 87

11.3.1 Company Overview 87

11.3.2 Financial Overview 87

11.3.3 Products/Services Offered 87

11.3.4 SWOT Analysis 88

11.3.5 Key Developments 88

11.3.6 Key Strategies 88

11.4 Basilea Pharmaceutica Ltd 89

11.4.1 Company Overview 89

11.4.2 Financial Overview 89

11.4.3 Products/Services Offered 90

11.4.4 Key Developments 90

11.4.5 SWOT Analysis 90

11.4.6 Key Strategies 90

11.5 Sanofi S. A. 91

11.5.1 Company Overview 91

11.5.2 Financial Overview 91

11.5.3 Products/Services Offered 91

11.5.4 SWOT Analysis 92

11.5.5 Key Developments 92

11.5.6 Key strategies 92

11.6 Melinta Therapeutics, Inc. 93

11.6.1 Company Overview 93

11.6.2 Financial Overview 93

11.6.3 Products/Services Offered 93

11.6.4 Key Developments 94

11.6.5 SWOT Analysis 94

11.6.6 Key Strategies 94

11.7 Bayer AG 95

11.7.1 Company Overview 95

11.7.2 Financial Overview 95

11.7.3 Products/Services Offered 95

11.7.4 SWOT Analysis 96

11.7.5 Key Developments 96

11.7.6 Key Strategies 96

11.8 Johnson & Johnson Services, Inc. 97

11.8.1 Company Overview 97

11.8.2 Financial Overview 97

11.8.3 Products/Services Offered 97

11.8.4 SWOT Analysis 98

11.8.5 Key Developments 98

11.8.6 Key Strategies 98

11.9 Yashica Pharmaceuticals 99

11.9.1 Company Overview 99

11.9.2 Financial Overview 99

11.9.3 Products/Services Offered 99

11.9.4 Key Developments 99

11.9.5 SWOT Analysis 100

11.9.6 Key Strategies 100

11.10 AtoxBio 101

11.10.1 Company Overview 101

11.10.2 Financial Overview 101

11.10.3 Products/Services Offered 101

11.10.4 Key Developments 101

11.10.5 SWOT Analysis 101

11.10.6 Key Strategies 101

12 Appendix

12.1 Discussion Blue Print 103


13 List of Tables

TABLE 1 PRIMARY INTERVIEWS 19

TABLE 2 TREATMENT COST FOR THE Q FEVER 24

TABLE 3 GLOBAL Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 36

TABLE 4 GLOBAL Q FEVER MARKET, FOR ACUTE BY REGION, 2020–2027 (USD THOUSAND) 37

TABLE 5 GLOBAL Q FEVER MARKET, FOR CHRONIC BY REGION, 2020–2027 (USD THOUSAND) 37

TABLE 6 GLOBAL Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 39

TABLE 7 GLOBAL Q FEVER MARKET, FOR SEROLOGY TESTS BY REGION, 2020–2027 (USD THOUSAND) 40

TABLE 8 GLOBAL Q FEVER MARKET, FOR OTHERS BY REGION, 2020–2027 (USD THOUSAND) 40

TABLE 9 GLOBAL Q FEVER MARKET, FOR ANTIBIOTICS BY REGION, 2020–2027 (USD THOUSAND) 43

TABLE 10 GLOBAL Q FEVER MARKET, FOR SURGERY BY REGION, 2020–2027 (USD THOUSAND) 43

TABLE 11 GLOBAL Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 45

TABLE 12 GLOBAL Q FEVER MARKET, FOR PATIENTS BY REGION, 2020–2027 (USD THOUSAND) 46

TABLE 13 GLOBAL Q FEVER MARKET, FOR HOSPITALS BY REGION, 2020–2027 (USD THOUSAND) 46

TABLE 14 GLOBAL Q FEVER MARKET, FOR OTHERS BY REGION, 2020–2027 (USD THOUSAND) 47

TABLE 15 GLOBAL Q FEVER MARKET, BY REGION, 2020–2027 (USD THOUSAND) 50

TABLE 16 AMERICAS: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 51

TABLE 17 AMERICAS: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 51

TABLE 18 AMERICAS: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 52

TABLE 19 AMERICAS: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 52

TABLE 20 NORTH AMERICA: Q FEVER MARKET, BY COUNTRY, 2020–2027 (USD THOUSAND) 52

TABLE 21 NORTH AMERICAS: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 53

TABLE 22 NORTH AMERICAS: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 53

TABLE 23 NORTH AMERICAS: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 53

TABLE 24 NORTH AMERICAS: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 54

TABLE 25 US: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 54

TABLE 26 US: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 54

TABLE 27 US: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 54

TABLE 28 US: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 55

TABLE 29 CANADA: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 55

TABLE 30 CANADA: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 55

TABLE 31 CANADA: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 55

TABLE 32 CANADA: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 56

TABLE 33 LATIN AMERICA: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 56

TABLE 34 LATIN AMERICA: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 56

TABLE 35 LATIN AMERICA: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 56

TABLE 36 LATIN AMERICA: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 57

TABLE 37 EUROPE: Q FEVER MARKET, BY COUNTRY, 2020–2027 (USD THOUSAND) 57

TABLE 38 EUROPE: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 58

TABLE 39 EUROPE: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 58

TABLE 40 EUROPE: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 58

TABLE 41 EUROPE: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 58

TABLE 42 GERMANY: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 59

TABLE 43 GERMANY: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 59

TABLE 44 GERMANY: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 59

TABLE 45 GERMANY: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 59

TABLE 46 FRANCE: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 60

TABLE 47 FRANCE: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 60

TABLE 48 FRANCE: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 60

TABLE 49 FRANCE: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 60

TABLE 50 UK: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 61

TABLE 51 UK: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 61

TABLE 52 UK: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 61

TABLE 53 UK: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 61

TABLE 54 ITALY: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 62

TABLE 55 ITALY: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 62

TABLE 56 ITALY: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 62

TABLE 57 ITALY: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 62

TABLE 58 SPAIN: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 63

TABLE 59 SPAIN: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 63

TABLE 60 SPAIN: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 63

TABLE 61 SPAIN: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 63

TABLE 62 REST OF EUROPE: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 64

TABLE 63 REST OF EUROPE: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 64

TABLE 64 REST OF EUROPE: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 64

TABLE 65 REST OF EUROPE: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 64

TABLE 66 ASIA-PACIFIC: Q FEVER MARKET, BY COUNTRY, 2020–2027 (USD THOUSAND) 65

TABLE 67 ASIA-PACIFIC: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 65

TABLE 68 ASIA-PACIFIC: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 66

TABLE 69 ASIA-PACIFIC: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 66

TABLE 70 ASIA-PACIFIC: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 66

TABLE 71 JAPAN: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 67

TABLE 72 JAPAN: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 67

TABLE 73 JAPAN: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 67

TABLE 74 JAPAN: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 67

TABLE 75 CHINA: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 68

TABLE 76 CHINA: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 68

TABLE 77 CHINA: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 68

TABLE 78 CHINA: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 68

TABLE 79 INDIA: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 69

TABLE 80 INDIA: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 69

TABLE 81 INDIA: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 69

TABLE 82 INDIA: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 69

TABLE 83 AUSTRALIA: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 70

TABLE 84 AUSTRALIA: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 70

TABLE 85 AUSTRALIA: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 70

TABLE 86 AUSTRALIA: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 70

TABLE 87 SOUTH KOREA: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 71

TABLE 88 SOUTH KOREA: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 71

TABLE 89 SOUTH KOREA: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 71

TABLE 90 SOUTH KOREA: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 71

TABLE 91 REST OF ASIA-PACIFIC: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 72

TABLE 92 REST OF ASIA-PACIFIC: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 72

TABLE 93 REST OF ASIA-PACIFIC: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 72

TABLE 94 REST OF ASIA-PACIFIC: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 72

TABLE 95 MIDDLE EAST & AFRICA: Q FEVER MARKET, BY COUNTRY, 2020–2027 (USD THOUSAND) 73

TABLE 96 MIDDLE EAST & AFRICA: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 74

TABLE 97 MIDDLE EAST & AFRICA: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 74

TABLE 98 MIDDLE EAST & AFRICA: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 74

TABLE 99 MIDDLE EAST & AFRICA: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 74

TABLE 100 UAE: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 75

TABLE 101 UAE: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 75

TABLE 102 UAE: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 75

TABLE 103 UAE: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 75

TABLE 104 SAUDI ARABIA: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 76

TABLE 105 SAUDI ARABIA: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 76

TABLE 106 SAUDI ARABIA: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 76

TABLE 107 SAUDI ARABIA: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 76

TABLE 108 OMAN: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 77

TABLE 109 OMAN: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 77

TABLE 110 OMAN: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 77

TABLE 111 OMAN: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 77

TABLE 112 KUWAIT: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 78

TABLE 113 KUWAIT: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 78

TABLE 114 KUWAIT: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 78

TABLE 115 KUWAIT: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 78

TABLE 116 QATAR: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 79

TABLE 117 QATAR: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 79

TABLE 118 QATAR: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 79

TABLE 119 QATAR: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 79

TABLE 120 AFRICA: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 80

TABLE 121 AFRICA: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 80

TABLE 122 AFRICA: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 80

TABLE 123 AFRICA: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 80

TABLE 124 REST OF MIDDLE EAST & AFRICA: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 81

TABLE 125 REST OF MIDDLE EAST & AFRICA: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 81

TABLE 126 REST OF MIDDLE EAST & AFRICA: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 81

TABLE 127 REST OF MIDDLE EAST & AFRICA: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 81


14 List of Figures

FIGURE 1 GLOBAL Q FEVER MARKET: MARKET STRUCTURE 17

FIGURE 2 RESEARCH PROCESS 19

FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH 22

FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL Q FEVER MARKET 25

FIGURE 5 PORTER’S FIVE FORCES ANALYSIS: GLOBAL Q FEVER MARKET 30

FIGURE 6 SUPPLY CHAIN: GLOBAL Q FEVER MARKET 32

FIGURE 7 GLOBAL Q FEVER MARKET SHARE, BY TYPE, 2020 (%) 36

FIGURE 8 GLOBAL Q FEVER MARKET, BY TYPE, 2020 & 2027 (USD THOUSAND) 37

FIGURE 9 GLOBAL Q FEVER MARKET SHARE, BY DIAGNOSIS, 2020 (%) 39

FIGURE 10 GLOBAL Q FEVER MARKET, BY DIAGNOSIS, 2020 & 2027 (USD THOUSAND) 40

FIGURE 11 GLOBAL Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 42

FIGURE 12 GLOBAL Q FEVER MARKET SHARE, BY TREATMENT, 2020 (%) 42

FIGURE 13 GLOBAL Q FEVER MARKET, BY TREATMENT, 2020 & 2027 (USD THOUSAND) 43

FIGURE 14 GLOBAL Q FEVER MARKET SHARE, BY END USER, 2020 (%) 45

FIGURE 15 GLOBAL Q FEVER MARKET, BY END USER, 2020 & 2027 (USD THOUSAND) 46

FIGURE 16 GLOBAL Q FEVER MARKET SHARE, BY REGION, 2020 (%) 50

FIGURE 17 AMERICAS: Q FEVER MARKET SHARE, BY REGION, 2020 (%) 51

FIGURE 18 NORTH AMERICA: Q FEVER MARKET SHARE, BY COUNTRY, 2020 (%) 53

FIGURE 19 EUROPE: Q FEVER MARKET SHARE, BY COUNTRY, 2020 (%) 57

FIGURE 20 ASIA-PACIFIC: Q FEVER MARKET SHARE, BY COUNTRY, 2020 (%) 65

FIGURE 21 MIDDLE EAST & AFRICA: Q FEVER MARKET SHARE, BY COUNTRY, 2020 (%) 73